{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:58:29Z","timestamp":1791230309685,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006673","name":"Fonds L\u00e9on Fredericq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Understanding and measuring the individual level of immune protection and its persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory for the management of the vaccination booster campaign. Our prospective study was designed to assess the immunogenicity of the BNT162b2 mRNA vaccine in triggering the cellular and humoral immune response in healthcare workers up to 12 months after the initial vaccination, with one additional boosting dose between 6 and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study enrolled 208 healthcare workers (HCWs) from the Li\u00e8ge University Hospital (CHU) of Li\u00e8ge in Belgium. Participants received two doses of BioNTech\/Pfizer COVID-19 vaccine (BNT162b2) and a booster dose 6-12 months later. Fifty participants were SARS-CoV-2 experienced and 158 were na\u00efve before the vaccination. Blood sampling was performed at the day of the first (T0) and second (T1) vaccine doses administration, then at 2 weeks (T2), 4 weeks (T3), 6 months (T4) and 12 months (T5) after the second dose. Between T4 and T5, participants also got the third boosting vaccine dose. A total of 1145 blood samples were collected. All samples were tested for the presence of anti-Spike antibodies, using the DiaSorin LIAISON SARS-CoV-2 Trimeric S IgG assay, and for anti-Nucleocapsid antibodies, using Elecsys anti-SARS-CoV-2 assay\u200b\u200b. Neutralizing antibodies against the SARS-CoV-2 Wuhan-like variant strain were quantified in all samples using a Vero E6 cell-based neutralization assay. Cell-mediated immune response was evaluated at T4 and T5 on 80 and 55 participants, respectively, by measuring the secretion of IFN-\u03b3 on peripheral blood lymphocytes using the QuantiFERON Human IFN-\u03b3 SARS-CoV-2, from Qiagen. We analyzed separately the na\u00efve and experienced participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>We found that anti-spike antibodies and neutralization capacity levels were significantly higher in SARS-CoV-2 experienced HCWs compared to na\u00efve HCWs at all time points analyzed except the one after boosting dose. Cellular immune response was also higher in experienced HCWs six months following vaccination. Besides the impact of SARS-CoV-2 infection history on immune response to BNT162b2 mRNA vaccine, we observed a significant negative association between age and persistence of humoral response. The booster dose induced an increase in humoral and cellular immune responses, particularly in naive individuals. Breakthrough infections resulted in higher cellular and humoral responses after the booster dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data strengthen previous findings demonstrating that immunization through vaccination combined with natural infection is better than 2 vaccine doses immunization or natural infection alone. The benefit of the booster dose was greater in naive individuals. It may have implications for personalizing mRNA vaccination regimens used to prevent severe COVID-19 and reduce the impact of the pandemic on the healthcare system. More specifically, it may help prioritizing vaccination, including for the deployment of booster doses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.863554","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T04:17:16Z","timestamp":1653970636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":49,"title":["Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections"],"prefix":"10.3389","volume":"13","author":[{"given":"Salom\u00e9","family":"Desmecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Tashkeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdouline","family":"El Moussaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Marechal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Per\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumie","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Fombellida-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Polese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"W\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Mni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fouillien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lutteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Moutschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Meuris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Vermeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Desmecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Darcis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2114290","article-title":"Effectiveness of BNT162b2 Vaccine Against Delta Variant in Adolescents","volume":"385","author":"Reis","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age","volume":"386","author":"Walter","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/nejmoa2114228","article-title":"Waning Immunity After the BNT162b2 Vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1056\/nejmoa2114114","article-title":"Waning of BNT162b2 Vaccine Protection Against SARS-CoV-2 Infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116063","article-title":"Covid-19 Vaccine Effectiveness in New York State","volume":"386","author":"Rosenberg","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068848","article-title":"Effectiveness of mRNA-1273 Against Delta, Mu, and Other Emerging Variants of SARS-CoV-2: Test Negative Case-Control Study","volume":"375","author":"Bruxvoort","year":"2021","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2115596","article-title":"Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl5344","article-title":"BNT162b2 Vaccination Induces Durable SARS-CoV-2\u2013Specific T Cells With a Stem Cell Memory Phenotype","volume":"6","author":"Guerrera","year":"2021","journal-title":"Sci Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2114706","article-title":"Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMc2117385","article-title":"Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel","volume":"386","author":"Muhsen","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a Third Dose of the BNT162b2 mRNA COVID-19 Vaccine for Preventing Severe Outcomes in Israel: An Observational Study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3201\/eid1002.030731","article-title":"Serologic and Molecular Biologic Methods for SARS-Associated Coronavirus Infection, Taiwan","volume":"10","author":"Wu","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3107","article-title":"Scaling Regression Inputs by Dividing by Two Standard Deviations","volume":"27","author":"Gelman","year":"2008","journal-title":"Stat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103656","DOI":"10.1016\/j.ebiom.2021.103656","article-title":"Influence of Past Infection With SARS-CoV-2 on the Response to the BNT162b2 mRNA Vaccine in Health Care Workers: Kinetics and Durability of the Humoral Immune Response","volume":"73","author":"Onta\u00f1\u00f3n","year":"2021","journal-title":"EBioMedicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi8961","article-title":"Robust Immune Responses Are Observed After One Dose of BNT162b2 mRNA Vaccine Dose in SARS-CoV-2 Experienced Individuals","volume":"14","author":"Samanovic","year":"2021","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/nejmoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine Over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","article-title":"Immunological Memory to SARS-CoV-2 Assessed for Up to 8 Months After Infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing Antibodies Correlate With Protection From SARS-CoV-2 in Humans During a Fishery Vessel Outbreak With a High Attack Rate","volume":"58","author":"Addetia","year":"2020","journal-title":"J Clin Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034545","article-title":"Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 With Neutralizing Monoclonal Antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.863554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T04:17:18Z","timestamp":1653970638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.863554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2022.863554"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.863554","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.17.22269278","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"article-number":"863554"}}